SCHEMBL5267570

SCHEMBL5267570

O=C1CCC=C(c2cccc(OCc3ccccc3)c2)O1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 7/20 0.47
PRKDC P78527 1/20 0.46
ATM Q13315 1/20 0.46
BRD4 O60885 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.45
GSTP1 P09211 2/20 0.45
HPD P32754 1/20 0.44
MAOA P21397 2/20 0.44
NR4A2 P43354 1/20 0.44
GRM5 P41594 2/20 0.43
SOD1 P00441 1/20 0.43
ALDH1A1 P00352 2/20 0.43
NPC1 O15118 1/20 0.43
HPGD P15428 1/20 0.43
NFKB1 P19838 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379281 0.74 MAOB (0.67) MAOBMRGPRX4GSTP1MAOANR4A2
SCHEMBL2137838 0.73 MRGPRX4 (0.69) MAOBMRGPRX4GSTP1MAOANR4A2
SCHEMBL30317738 0.72 MAOB (0.49) MAOBPRKDCATMBRD4MRGPRX4
SCHEMBL5266330 0.72 MAOB (0.49) MAOBPRKDCATMBRD4MRGPRX4
SCHEMBL19389796 0.71 HPD (0.51) MAOBBRD4HPDMAOANR4A2
SCHEMBL9214604 0.69 FABP7 (0.51) MAOBPRKDCATMBRD4MRGPRX4
SCHEMBL1268719 0.69 MAOB (0.81) MAOBMAOANR4A2GRM5
SCHEMBL16346074 0.69 GSTP1 (0.66) MAOBMRGPRX4GSTP1NR4A2
SCHEMBL27418806 0.69 MAOB (0.56) MAOBMAOAGRM5ALDH1A1NPC1
SCHEMBL7328699 0.69 MAOB (0.69) MAOBMAOAGRM5ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1596106-B Use of trifluoroacetyl alkyl-substituted phenyl derivatives, phenol derivatives, and benzoyl derivatives in the treatment and/or prophylaxis of obesity and complications and/or sequelas SOLVAY PHARM BV 2011-05-11 CN disclosed
EP-1420771-B9 USE OF TRIFLUOROACETYL ALKYL-SUBSTITUTED PHENYL DERIVATIVES, PHENOL DERIVATIVES, AND BENZOYL DERIVATIVES IN THE TREATMENT AND/OR PROPHYLAXIS OF OBESITY AND ACCOMPANYING DISEASES AND/OR SECONDARY DISEASES SOLVAY PHARM GMBH (DE) 2007-10-17 EP disclosed
EP-1420771-B1 USE OF TRIFLUOROACETYL ALKYL-SUBSTITUTED PHENYL DERIVATIVES, PHENOL DERIVATIVES, AND BENZOYL DERIVATIVES IN THE TREATMENT AND/OR PROPHYLAXIS OF OBESITY AND ACCOMPANYING DISEASES AND/OR SECONDARY DISEASES SOLVAY PHARM GMBH (DE) 2006-09-06 EP disclosed
US-6930207-B2 Trifluoroacetylalkyl-substituted phenyl, phenol and benzoyl compounds and related methods of treatment SOLVAY PHARMACEUTICAL GMBH (DE) 2005-08-16 US disclosed
CN-1596106-A Use of trifluoroacetyl alkyl-substituted phenyl derivatives, phenol derivatives, and benzoyl derivatives in the treatment and/or prophylaxis of obesity and accompanying diseases and/or secondary disea SOLVAY PHARM GMBH (DE) 2005-03-16 CN disclosed
US-20040214901-A1 Trifluoroacetylalkyl-substituted phenyl, phenol and benzoyl compounds and related methods of treatment SOLVAY PHARMACEUTICALS GMBH (DE) 2004-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214901-A1 Trifluoroacetylalkyl-substituted phenyl, phenol and benzoyl compounds and related methods of treatment PNLIP, LIPC, CEL MAOB 334/4885PRKDC 3684/4885ATM 1315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.